secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-08-28T23:59:59+00:00
Accession:  0001764013-25-000132
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant shareholders elect all three director nominees, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- Jacob Bauer, Douglas Hughes, and Robert Susman elected to Board until 2026 annual meeting.
- Ernst & Young ratified as independent auditor for FY ending March 31, 2026 (165.4M for, 7K against).
- Non-binding advisory vote on named executive officer compensation approved (159.0M for, 1.2M against).
- Approximately 97% of outstanding shares represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000132/0001764013-25-000132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000132/imvt-20250827.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer